Aurora Cannabis: Deal Or No Deal

By -
Aurora Cannabis was left out of the major deal making in 2018.
The cannabis company updated FQ2 guidance to revenues of $50 to $55 million with a continued focus on pure production growth.
The stock is down as the market is becoming less impressed with commodity farming operations due to the prime Oregon example.
The stock is below key resistance at $5.40 as medical cannabis patient totals failed to impress.
As the end of 2018 came and went, Aurora Cannabis (ACB) was a notable absentee from the deal making in the cannabis market. Just about all of the other major Canadian cannabis players got large investments or signed up powerful partnerships, but the related stocks didn't generally maintain rallies following the deals. Based on the early legalization data in Canada and Oregon, the best option for Aurora Cannabis might actually be selling production capacity while the Canadian market remains hot.
Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please review the disclaimer page for more details. 
 

Comments

Post a Comment

Popular posts from this blog

Novavax: At It Again

By -
With Novavax (NVAX), the company is always a few days away from issuing more stock and usually at not very opportune times. The small biotech just made such a move again.

On December 31, Novavax filed to sell $100 million of shares at a 2% commission. As usual, the move made no sense with a cash balance that has to be in excess of $100 million and knowledge that the company was about to release positive Phase 2 data on NanoFlu.

Read more